Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction.
Twenty-five patients who had extensive pulmonary tuberculosis and hepatitis induced by antituberculosis drugs were treated with ciprofloxacin together with other relatively non-hepatotoxic drugs, either during the interim phase awaiting recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others. Only 22 patients were assessable. All tolerated ciprofloxacin well during the phase of hepatic dysfunction. All patients improved with these ciprofloxacin-containing regimens, but the optimal dosage, specific efficacy and long-term safety of the drug in such cases require further evaluation.
Yew
W W
WW
Tuberculosis & Chest Unit, Grantham Hospital, Aberdeen, Hong Kong.
Chau
C H
CH
Wong
P C
PC
Lee
J
J
Wong
C F
CF
Cheung
S W
SW
Chan
C Y
CY
Cheng
A F
AF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
D000995:Antitubercular Agents; D002939:Ciprofloxacin